Hao Yexia, Gao Jimin, Zhang Xiaohong, Liu Na, Li Jinsong, Zheng Lishu, Duan Zhaojun
Key Laboratory for Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China; Wenzhou Medical University, Zhejiang, China.
Wenzhou Medical University, Zhejiang, China.
PLoS One. 2015 Apr 29;10(4):e0122751. doi: 10.1371/journal.pone.0122751. eCollection 2015.
Seroepidemiology studies had been used to research the newly discovered human bocaviruses (HBoVs). Antibodies against the HBoV1-4 VP2 protein virus-like particles (VLPs) were found to be cross-reactive. The aim of the present study was to characterize the seroprevalence of HBoV1 and 2 among healthy populations in China. Recombinant HBoV1 and 2 VLPs were used to establish enzyme-linked immunosorbent assays (ELISAs) for detection of cross-reactivity between HBoV1 and HBoV2 in 1391 serum samples collected from healthy individuals in China. Of these, 884 samples were collected from Beijing and 507 were from Nanjing. Infection with HBoV1 and 2 was prevalent in healthy Chinese people, with the seroprevalence of HBoV1 and 2 in Beijing at 69.2 (612/884) and 64.4% (569/884), respectively. Highest seroprevalence was observed in 3-5-year-olds. The seroprevalence of HBoV1 was significantly decreased between 10-13-year-olds (80.3%) and 14-20-year-olds (62.3%, p< 0.05). For individuals over 20 years, seroprevalence was relatively constant at about 60%. Similar trends were observed in children from Nanjing, with seroprevalence of HBoV1 and 2 for healthy children at 80.7% (409/507) and 81.3% (412/507), respectively. Moreover, both mouse and human antibodies against HBoV1 and HBoV2 VLPs were found to be cross-reactive and 58.4% (813/1391) serum samples were seropositive for both HBoV1 and HBoV2. This finding suggests HBoV is highly prevalent in China and the antibodies produced as a result of infection with either HBoV1 or HBoV 2 will offer future protection. The cross-reactivity between HBoVs is crucial for accurately determining HBoV seroepidemiology.
血清流行病学研究已被用于研究新发现的人博卡病毒(HBoV)。发现针对HBoV1 - 4病毒样颗粒(VLP)的VP2蛋白的抗体具有交叉反应性。本研究的目的是确定中国健康人群中HBoV1和HBoV2的血清流行率。使用重组HBoV1和HBoV2 VLP建立酶联免疫吸附测定(ELISA),以检测从中国健康个体收集的1391份血清样本中HBoV1和HBoV2之间的交叉反应性。其中,884份样本来自北京,507份来自南京。HBoV1和HBoV2感染在中国健康人群中普遍存在,北京地区HBoV1和HBoV2的血清流行率分别为69.2%(612/884)和64.4%(569/884)。在3至5岁儿童中观察到最高的血清流行率。HBoV1的血清流行率在10至13岁儿童(80.3%)和14至20岁儿童(62.3%,p<0.05)之间显著下降。对于20岁以上的个体,血清流行率相对稳定在约60%。在南京儿童中也观察到类似趋势,健康儿童中HBoV1和HBoV2的血清流行率分别为80.7%(409/507)和81.3%(412/507)。此外,发现小鼠和人针对HBoV1和HBoV2 VLP的抗体具有交叉反应性,58.4%(813/1391)的血清样本对HBoV1和HBoV2均呈血清阳性。这一发现表明HBoV在中国高度流行,感染HBoV1或HBoV2产生的抗体将提供未来的保护。HBoV之间的交叉反应性对于准确确定HBoV血清流行病学至关重要。